Australian’s Biotron Focuses On Developing Drug For Spreading Dengue
This article was originally published in PharmAsia News
Australian biotech Biotron and two universities are focusing on a drug to treat the dengue fever plaguing parts of the country. No drug or vaccine is available today to treat the disease and patients have to rely instead on treatments for the symptoms. The researchers are attempting to develop a drug that slows growth or at least inhibits the infection of the virus by binding with the proteins responsible. One of the scientists said the dengue virus is able to suppress some of the human's antiviral proteins, making it effective as a disease. (Click here for more
You may also be interested in...
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).